LanZhou Foci Pharmaceutical Co.,Ltd.

Symbol: 002644.SZ

SHZ

7.78

CNY

Market price today

  • 68.3675

    P/E Ratio

  • -2.3694

    PEG Ratio

  • 3.97B

    MRK Cap

  • 0.01%

    DIV Yield

LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ). Companys revenue shows the average of 479.567 M which is 0.118 % gowth. The average gross profit for the whole period is 143.126 M which is 0.116 %. The average gross profit ratio is 0.314 %. The net income growth for the company last year performance is -0.382 % which equals 0.109 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of LanZhou Foci Pharmaceutical Co.,Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.023. In the realm of current assets, 002644.SZ clocks in at 1238.869 in the reporting currency. A significant portion of these assets, precisely 406.041, is held in cash and short-term investments. This segment shows a change of 0.019% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 79.875, if any, in the reporting currency. This indicates a difference of 19.813% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 1.346 in the reporting currency. This figure signifies a year_over_year change of 0.812%. Shareholder value, as depicted by the total shareholder equity, is valued at 1745.371 in the reporting currency. The year over year change in this aspect is 0.017%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 441.812, with an inventory valuation of 369.72, and goodwill valued at 9.01, if any. The total intangible assets, if present, are valued at 79.55.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

balance-sheet.row.cash-and-short-term-investments

1413.19406398.5374.9
452
434.7
465.5
70.2
418.6
499
275.6
161.8
190
325.5
67.8
18.7
9.3
6.6

balance-sheet.row.short-term-investments

-70.42-15.82-10.4
32.1
-18.2
-5.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

2046.86441.8526.5390.8
335.1
312
200.1
157
110.8
126.6
157.4
237.1
131.9
100.3
77.2
116.3
77.5
66.8

balance-sheet.row.inventory

1526.12369.7350.4258.8
258.3
286.8
241.3
196.6
191.2
159.3
138
124.7
150.2
140.1
85.6
79.9
76
48.1

balance-sheet.row.other-current-assets

74.0421.315.710
8.7
2.9
19.6
673.9
699.8
226.2
-2
-3
-4.4
-6.1
-3.8
-7.8
-1.3
-6.9

balance-sheet.row.total-current-assets

5060.221238.91291.11034.6
1054.1
1036.3
926.5
1097.7
1420.4
1011
569.1
520.8
467.7
559.7
226.8
207.1
161.5
114.6

balance-sheet.row.property-plant-equipment-net

4211.941061.81066.81091.6
1110.4
1134.5
1407.3
1100
471.2
220.6
319.8
294.1
267.8
183.2
151.7
137
136
138.5

balance-sheet.row.goodwill

26.9694.54.5
4.5
4.5
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

320.6679.676.872
74
75.8
124.8
127.6
118.7
120.3
147.9
84.5
85.4
84.7
71.9
74.2
101.3
104.2

balance-sheet.row.goodwill-and-intangible-assets

347.6388.681.376.4
78.5
80.3
124.8
127.6
118.7
120.3
147.9
84.5
85.4
84.7
71.9
74.2
101.3
104.2

balance-sheet.row.long-term-investments

335.9979.966.782.1
41.5
95.5
47.6
5.7
6.1
39.2
159.7
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

205.4153.652.451.1
51.3
53.6
5
5.4
4.9
4.2
2.9
2.5
2
1.6
1.5
0.7
0.5
1.5

balance-sheet.row.other-non-current-assets

54.245.328.416.2
51.3
0.4
12.9
13.5
15.4
-32.8
-152.8
1.2
0
0
4.3
3
1.3
1.3

balance-sheet.row.total-non-current-assets

5155.211289.21295.51317.5
1333
1364.3
1597.5
1252.2
616.3
351.4
477.5
382.3
355.2
269.5
229.4
214.9
239.1
245.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

10215.432528.12586.62352.1
2387.2
2400.7
2524
2349.8
2036.7
1362.4
1046.6
903.1
822.9
829.2
456.2
422
400.5
359.9

balance-sheet.row.account-payables

1338.65310.4311214.3
300.2
372.5
451.7
323.7
104.1
52.7
63.4
15.2
43.9
58.3
29.5
38.6
42.6
26.2

balance-sheet.row.short-term-debt

98.7424.713.814.7
34
14.5
17.3
0
0
0
26
124
76
76
46
46
59
34

balance-sheet.row.tax-payables

130.9535.169.447.6
49.2
48.5
7.7
13.3
2.6
2.5
2.4
3.6
4.1
12.2
10.3
3.5
1.4
2.4

balance-sheet.row.long-term-debt-total

14.551.30.50.8
66.6
80
387
109.4
108.1
0
0
0
2
2
2
2
2
15

Deferred Revenue Non Current

1056.95261278.2295
310.2
328.4
189.4
21.8
24.4
26.2
6.8
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

10.03---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

19.45.8110.94.5
1.1
13.4
30.3
47.2
32.1
34.8
11.2
6.1
4.3
3.7
3.8
11.6
1.7
4.8

balance-sheet.row.total-non-current-liabilities

1174.53292322.1349.8
377.6
409.3
576.4
619.8
610
41.2
197.4
38.9
14.7
13.6
13.4
11
10.6
25.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

3.231.30.50.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

3126.08759.7852.6724.6
800.1
893.8
1083.6
990.7
746.1
128.8
311.4
199.7
147.4
181.1
129.7
169.1
183.7
164.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

2042.63510.7510.7510.7
510.7
510.7
510.7
510.7
510.7
510.7
177.7
88.9
88.9
80.8
60.6
60.6
60.6
60.6

balance-sheet.row.retained-earnings

3119.21776.2746.9654.5
631.9
565.1
507.6
448.5
387.8
337.5
302.3
274.1
249.4
233.1
204.2
158.1
125.5
106.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

1237.35158.4152143.6
133.8
123.9
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

605.87300.1305.8305.8
305.8
305.2
422.2
400
392.1
385.5
255.2
340.4
337.3
334.3
61.7
34.3
30.7
28.5

balance-sheet.row.total-stockholders-equity

7005.061745.41715.41614.6
1582.1
1504.9
1440.4
1359.1
1290.6
1233.7
735.2
703.4
675.5
648.1
326.5
253
216.8
195.2

balance-sheet.row.total-liabilities-and-stockholders-equity

10215.432528.12586.62352.1
2387.2
2400.7
2524
2349.8
2036.7
1362.4
1046.6
903.1
822.9
829.2
456.2
422
400.5
359.9

balance-sheet.row.minority-interest

84.2823.118.612.9
5
2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

7089.351768.417341627.5
1587.1
1506.9
1440.4
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

10215.43---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

265.5764.168.771.7
73.6
77.3
42.5
5.7
6.1
39.2
159.7
0
0
0
0
0
0
0

balance-sheet.row.total-debt

113.292614.415.5
34
14.5
17.3
109.4
108.1
0
26
124
78
78
48
48
61
49

balance-sheet.row.net-debt

-1299.9-380-382.1-359.4
-386
-420.1
-448.3
39.2
-310.5
-499
-249.6
-37.8
-112
-247.5
-19.8
29.3
51.7
42.4

Cash Flow Statement

The financial landscape of LanZhou Foci Pharmaceutical Co.,Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.401. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -34155286.360 in the reporting currency. This is a shift of -0.203 from the previous year. In the same period, the company recorded 52.49, 1.77, and -21.45, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -27.94 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -1.26, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

cash-flows.row.net-income

58.1268.1105.993.5
111.7
74.7
74.3
74.1
60.9
42.9
34.7
30.6
30.4
32.1
51.2
36.1
21.6
23.3

cash-flows.row.depreciation-and-amortization

3.6352.549.548.6
38.7
53.1
34.2
21
18.5
17.9
14.9
15.2
14.1
6.3
11.3
12.5
13.7
0

cash-flows.row.deferred-income-tax

00.210.2
2.3
-40.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0-0.2-1-0.2
-2.3
40.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

66.85-82.3-112.2-117
-33
-86.9
-60.5
-32.5
-23.5
5
41.5
-65.2
-61.4
-45.7
11.3
-38
-39.7
0

cash-flows.row.account-receivables

59.559.5-210.1-66.8
-48.9
-84.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-7.3-7.3-91.7-0.8
28.9
-45.1
-45.1
-6.4
-31.9
-21.3
-13.3
25.5
-10.2
-54.5
-5.7
-3.9
-27.9
0

cash-flows.row.account-payables

0-134.7188.6-49.5
-17.8
83.5
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

14.640.210.2
4.8
-40.7
-15.3
-26.1
8.4
26.3
54.8
-90.7
-51.3
8.8
17
-34.1
-11.8
0

cash-flows.row.other-non-cash-items

-71.0327.429.1-13.2
-54.5
7
-11.3
3.8
1
-1.8
2.7
8.9
6
9.7
-17.7
-7.1
5
-23.3

cash-flows.row.net-cash-provided-by-operating-activities

57.56000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-8.98-22.5-41.5-32.8
-122.6
-93.2
-261.1
-442.8
-267
-51.9
-48.4
-85.8
-113.8
-69.9
-21.9
-23.3
-6.4
-107.6

cash-flows.row.acquisitions-net

-15.45-15.53.974.1
215.7
-9.7
261.3
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

8.95-6-2.1-3.9
-176.9
95.1
-45.4
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

7.988-3.938.1
144.5
42.9
14.2
0
0
0
0
0
0
0
0
0
0.5
2

cash-flows.row.other-investing-activites

-15.171.80.8-32.8
-122.6
-93.2
-261.1
0
496.3
4.5
172.8
0.1
0
0
15.9
46.6
0
0.2

cash-flows.row.net-cash-used-for-investing-activites

-22.66-34.2-42.842.6
-61.9
-58
-292.1
-442.8
229.3
-47.4
124.5
-85.7
-113.8
-69.9
-6
23.3
-5.9
-105.3

cash-flows.row.debt-repayment

-22.59-21.5-14.2-35.3
-14.5
-17.3
0
0
0
-63
-124
-80
-76
-46
-46
-59
-34
-34

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-0.5000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-1.65-27.9-5.1-61.4
-31.9
-6.6
-6.6
-6.1
-4.6
-4.1
-6.4
-8.6
-7.8
-4.1
-2.5
-2.5
-4
-2.6

cash-flows.row.other-financing-activites

-11.1-1.33.93.3
22.9
3.3
13.3
2.3
91.9
495.2
26
156.4
73.1
375.4
47.5
44.3
46
32.7

cash-flows.row.net-cash-used-provided-by-financing-activities

-50.87-25-15.5-93.4
-23.5
-20.6
6.7
-3.8
87.3
428
-104.4
67.8
-10.7
325.3
-1
-17.3
8
-3.9

cash-flows.row.effect-of-forex-changes-on-cash

25.840.70.7-0.2
-0.1
-0.1
0
0
0
0.5
0
0.2
0.1
-0.1
-0.1
0
-0.1
-0.3

cash-flows.row.net-change-in-cash

9.867.214.8-39.1
-22.6
-30.9
-248.8
-380.2
373.6
445.3
113.8
-28.2
-135.5
257.7
49
9.5
2.7
-3.9

cash-flows.row.cash-at-end-of-period

1376.43396.3387.7372.9
412
434.7
465.5
714.3
1094.5
721
275.6
161.8
190
325.5
67.8
18.7
9.3
-3.9

cash-flows.row.cash-at-beginning-of-period

1366.56389.1372.9412
434.7
465.5
714.3
1094.5
721
275.6
161.8
190
325.5
67.8
18.7
9.3
6.6
0

cash-flows.row.operating-cash-flow

57.5665.772.411.9
62.9
47.8
36.7
66.4
56.9
64.1
93.7
-10.5
-11
2.4
56.2
3.5
0.6
105.6

cash-flows.row.capital-expenditure

-8.98-22.5-41.5-32.8
-122.6
-93.2
-261.1
-442.8
-267
-51.9
-48.4
-85.8
-113.8
-69.9
-21.9
-23.3
-6.4
-107.6

cash-flows.row.free-cash-flow

48.5843.230.9-21
-59.7
-45.3
-224.5
-376.3
-210.1
12.2
45.4
-96.3
-124.8
-67.5
34.3
-19.8
-5.8
-1.9

Income Statement Row

LanZhou Foci Pharmaceutical Co.,Ltd.'s revenue saw a change of 0.141% compared with the previous period. The gross profit of 002644.SZ is reported to be 361.3. The company's operating expenses are 261.96, showing a change of 102.488% from the last year. The expenses for depreciation and amortization are 52.49, which is a -0.156% change from the last accounting period. Operating expenses are reported to be 261.96, which shows a 102.488% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.403% year-over-year growth. The operating income is 83.27, which shows a -0.403% change when compared to the previous year. The change in the net income is -0.382%. The net income for the last year was 67.19.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

income-statement-row.row.total-revenue

1130.071163.11019.2817.6
668.1
628.8
544.6
501.1
363.3
327.6
399.1
291.5
266.4
271.2
262.4
232.2
219
177.5

income-statement-row.row.cost-of-revenue

765.41801.8733594.5
502.7
461.6
369.7
352.1
255
244.9
310.7
187.7
179.5
178
167.5
144.2
131.8
104.9

income-statement-row.row.gross-profit

364.66361.3286.2223.1
165.4
167.2
174.8
149.1
108.2
82.7
88.4
103.9
86.9
93.2
94.9
88
87.2
72.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

31.51---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

17.15---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

154.39---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-2.01-1.6-9.724.4
13.4
-26.1
0.3
2.2
6.3
7.6
10.9
9.5
6.9
4.8
24
13.5
1.3
-0.4

income-statement-row.row.operating-expenses

262.09262129.4134.6
109.4
98.3
112.8
89.3
74.1
65.3
67.5
71.6
55.5
55.8
57.5
56.1
56.7
38

income-statement-row.row.cost-and-expenses

1027.51063.8862.3729
612
560
482.6
441.4
329.1
310.2
378.2
259.2
235
233.8
225
200.3
188.5
142.9

income-statement-row.row.interest-income

2.935.47.510.2
12.8
16.3
12.4
30.9
31
23.5
10.2
2.5
2.3
0
0
0.1
0.1
0

income-statement-row.row.interest-expense

01.20.70.9
1.3
1.1
0.6
0
0
1
3.5
5.8
4.9
4.1
3.5
2.5
3.9
3

income-statement-row.row.selling-and-marketing-expenses

154.39---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-2.01-1.6-12.4-1.5
66.1
0.5
24.5
27.6
36.5
31.7
18.5
3.5
3.1
-1.1
18.3
8.7
-4.3
-7.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-2.01-1.6-9.724.4
13.4
-26.1
0.3
2.2
6.3
7.6
10.9
9.5
6.9
4.8
24
13.5
1.3
-0.4

income-statement-row.row.total-operating-expenses

-2.01-1.6-12.4-1.5
66.1
0.5
24.5
27.6
36.5
31.7
18.5
3.5
3.1
-1.1
18.3
8.7
-4.3
-7.3

income-statement-row.row.interest-expense

01.20.70.9
1.3
1.1
0.6
0
0
1
3.5
5.8
4.9
4.1
3.5
2.5
3.9
3

income-statement-row.row.depreciation-and-amortization

40.0652.562.232.2
38.7
63
34.2
21
18.5
17.9
14.9
15.2
14.1
6.3
11.3
12.5
13.7
9.7

income-statement-row.row.ebitda-caps

112.68---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

72.6283.3139.4112.4
64.4
78.2
86.1
85.2
64.7
41.5
28.4
26.2
27.6
31.5
31.7
27.1
24.9
27.7

income-statement-row.row.income-before-tax

70.681.6127110.8
130.5
78.7
86.5
87.4
70.6
49.1
39.3
35.8
34.5
36.3
55.7
40.6
26.2
27.3

income-statement-row.row.income-tax-expense

11.2813.521.117.3
22.8
7.8
13.6
13.3
9.7
6.1
4.7
5.2
4.2
4.2
4.5
4.5
4.6
4

income-statement-row.row.net-income

58.1267.2108.793.3
108
71.1
72.9
74.1
60.9
42.9
34.7
30.6
30.4
32.1
51.2
36.1
21.6
23.3

Frequently Asked Question

What is LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) total assets?

LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) total assets is 2528102214.000.

What is enterprise annual revenue?

The annual revenue is 576952643.000.

What is firm profit margin?

Firm profit margin is 0.323.

What is company free cash flow?

The free cash flow is 0.095.

What is enterprise net profit margin?

The net profit margin is 0.051.

What is firm total revenue?

The total revenue is 0.064.

What is LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) net profit (net income)?

The net profit (net income) is 67189706.000.

What is firm total debt?

The total debt is 26031519.000.

What is operating expences number?

The operating expences are 261964435.000.

What is company cash figure?

Enretprise cash is 365338610.000.